UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
JANUARY 14, 2000
------------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)
336-229-1127
------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS
On January 14, 2000, Laboratory Corporation of America-
Registered Trademark-Holdings (the Company) and Digene
Corporation (Digene) announced that an agreement was entered
into whereby the Company will utilize the Digene Hybrid
Capture II HPV Test for women with ASCUS (atypical squamous
cells of undetermined significance) or borderline Pap smear
results. The Company is a pioneer in identifying and
adopting innovative technologies for use in cytology and
oncology testing. Under the terms of the agreement, the
Company will offer Digene's advanced DNA-based technology,
which detects the human papillomavirus (HPV), the cause of
virtually all cervical cancer.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibit
20 Press release of the Company dated
January 14, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By:/s/ BRADFORD T. SMITH
------------------------------
Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer
Date: January 18, 2000
<PAGE>
FOR IMMEDIATE RELEASE: CONTACT:
Kelley Mullaney
Digene
(202) 530-4628
Pamela Sherry
LabCorp
(336) 436-4855
LABCORP-REGISTERED TRADEMARK- TO OFFER LATEST HPV TEST
PARTNERSHIP WITH DIGENE CORPORATION TO PROVIDE HPV HYBRID CAPTURE-
REGISTERED TRADEMARK- II ASSAY
GAITHERSBURG, MD AND BURLINGTON, NC (JANUARY 14, 2000) - Digene
Corporation (Nasdaq: DIGE) and Laboratory Corporation of America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-)
(NYSE: LH) announced today that they have entered into an
agreement whereby LabCorp will utilize the Digene Hybrid Capture
II HPV Test for women with ASCUS (atypical squamous cells of
undetermined significance) or borderline Pap smear results.
LabCorp-Registered Trademark- is a pioneer in identifying and
adopting innovative technologies for use in cytology and oncology
testing. Under the terms of the agreement, LabCorp will offer
Digene's advanced DNA-based technology, which detects the human
papillomavirus (HPV), the cause of virtually all cervical cancer.
Every year in the United States, approximately 15,000 women are
diagnosed with cervical cancer and 5,000 women die of the
disease. Worldwide, cervical cancer affects 500,000 women
annually, and after breast cancer, is the second most common
malignancy found in women.
"We are proud to be a partner with one of the largest reference
testing laboratories in the United States. This agreement
represents an important milestone for Digene as we continue to
reinforce the important role of HPV testing in cervical disease
management and prevention," said Evan Jones, Chairman and CEO of
Digene Corporation. "Utilization of Digene's HPV test permits
physicians and their patients to immediately know their risk
status. Women with a negative HPV test result have the peace of
mind in knowing that they are not at greatly reduced risk for
developing cervical cancer."
"LabCorp has a strong tradition of offering the latest technology
that can help quickly and accurately identify women who are at
risk for developing cervical cancer," stated Myla P. Lai-Goldman,
Executive Vice President, Chief Scientific Officer and Medical
Director of LabCorp-Registered Trademark-. "LabCorp has been a
leader in molecular diagnostics and human papillomavirus testing,
having provided HPV tests for over 10 years. Advancements in the
technology offered by the Hybrid Capture II assay, along with the
findings from recent clinical studies presented in prestigious
journals, support the utility of this test. "
-more-
<PAGE>
The Digene Hybrid Capture HPV Test is a FDA-approved test for
HPV. There are over 70 types of HPV, one of the most common
sexually transmitted infections. Of these 70 types, 23 affect
the genital tract but only 13 key types cause cervical cancer.
These high-risk types have been detected in 99.7% of cases of
cervical cancer, supporting the strong association between high-
risk HPV and cervical cancerconfirming that high-risk HPV must be
present for cervical cancer to develop. The Digene HPV test,
using DNA molecular technology, can detect the 13 key cancer-
causing types of HPV.
Digene Corporation, based in Gaithersburg, Maryland, develops,
manufactures and markets DNA and RNA tests for the detection,
screening and monitoring of human diseases. Digene's products are
designed to help improve clinical outcomes and reduce the overall
cost of disease management. Digene's lead product, the Hybrid
Capture-Registered Trademark- II HPV Test, aids physicians in
identifying women who are most at risk of having or developing
cervical disease and cervical cancer. The Digene HPV test is used
in the U.S. as an adjunct to the Pap smear for cervical cancer
screening and is being marketed in selected countries as a
primary cervical cancer screen either in conjunction with or
separate from the Pap smear. Visit Digene's website at
www.digene.com.
Laboratory Corporation of America-Registered Trademark- Holdings
(LabCorp-Registered Trademark-) is a national clinical laboratory
with annual revenues of $1.6 billion in 1998. With 18,000
employees and over 100,000 clients nationwide, the company offers
more than 2,000 clinical tests ranging from simple blood analyses
to sophisticated molecular diagnostics. LabCorp leverages its
expertise in innovative clinical testing technology with three
Centers of Excellence. The Center for Molecular Biology and
Pathology, in Research Triangle Park (RTP), North Carolina,
develops applications for polymerase chain reaction (PCR)
technology. Its Center for Occupational Testing in RTP is the
world's largest substance abuse testing facility, and the Center
for Esoteric Testing in Burlington, North Carolina, performs the
largest volume of specialty testing in the network. LabCorp's
clients include physicians, state and federal government, managed
care organizations, hospitals, clinics, pharmaceutical and
Fortune 1000 companies, and other clinical laboratories. Visit
LabCorp's web site at www.labcorp.com.
Each of the above forward-looking statements is subject to change
based on various important factors, including without limitation,
competitive actions in the marketplace and adverse actions of
governmental and other third-party payors. Further information
on potential factors that could affect the companies' financial
results is included in each company's most recently submitted
Form 10-K and subsequent filings.
###